Telithromycin for the treatment of acute bacterial maxillary sinusitis: A review of a new antibacterial agent

被引:7
作者
Tellier, G
Brunton, SA
Nusrat, R
机构
[1] Zoom Int Clin Res Grp, St Jerome, PQ J7Z 5T3, Canada
[2] Carolinas Med Ctr, Charlotte, NC 28203 USA
[3] Aventis Pharmaceut, Bridgewater, MA USA
关键词
telithromycin; sinusitis; antimicrobial; antibiotic; acute bacterial maxillary sinusitis;
D O I
10.1097/01.smj.0000176714.82199.23
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Telithrornycin, the first approved ketolide antibiotic, was developed to treat community-acquired respiratory tract infections, including acute bacterial maxillary sinusitis (ABMS). A previously published study showed that a 5-day Course of 800 mg telithromycin once daily is as effective as a 10-day course in the treatment of ABMS. Materials and Methods: Data were pooled from two controlled, multinational, prospective, randomized, double-blinded ABMS trials comparing 5-day telithromycin (800 ing once daily) with 10-day anioxicillin-clavulanate (500/125 ing 3 times daily) and cefuroxime axetil (250 mg twice daily). Clinical cure and bacteriologic eradication rates were compared by means of descriptive statistics. Results: The clinical cure rate for telithromycin was 80.9% versus 77.4% for comparators; bacteriologic eradication rate for telithromycin was 84.9% versus 81.7% for comparators. Most adverse events were mild to moderate in intensity and, most commonly, gastrointestinal in nature. Conclusions: These results support the conclusion that 5 days of treatment with telithromycin is as safe and effective in patients with ABMS as a 10-day course of treatment with arnoxicillin-clavulanate or ccfuroxiine axetil.
引用
收藏
页码:863 / 868
页数:6
相关论文
共 33 条
  • [1] Adam D, 2000, J INT MED RES, V28, p13A
  • [2] Antimicrobial treatment guidelines for acute bacterial rhinosinusitis - Executive summary
    Anon, JB
    Jacobs, MR
    Roche, R
    Poole, MD
    Merck, D
    Ambrose, PG
    Benninger, MS
    Hadley, JA
    Craig, WA
    Andes, DR
    Bernstein, JM
    Besser, RE
    Dowell, SF
    Drusano, GL
    Klepser, ME
    Nicolau, D
    Radowsky, A
    Reller, LB
    Wald, ER
    Zucker, DR
    [J]. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2004, 130 (01) : 1 - 45
  • [3] Resistance among Streptococcus pneumoniae:: Implications for drug selection
    Appelbaum, PC
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (12) : 1613 - 1620
  • [4] Telithromycin: An oral ketolide for respiratory infections
    Bearden, DT
    Neuhauser, MM
    Garey, KW
    [J]. PHARMACOTHERAPY, 2001, 21 (10): : 1204 - 1222
  • [5] Brook I, 2000, ANN OTO RHINOL LARYN, V109, P2
  • [6] A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis
    Buchanan, PP
    Stephens, TA
    Leroy, B
    [J]. AMERICAN JOURNAL OF RHINOLOGY, 2003, 17 (06): : 369 - 377
  • [7] CHERRY DK, 2002, ADV DATA, V328, P1
  • [8] A systematic review of the associations between dose regimens and medication compliance
    Claxton, AJ
    Cramer, J
    Pierce, C
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (08) : 1296 - 1310
  • [9] Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA
    Douthwaite, S
    Hansen, LH
    Mauvais, P
    [J]. MOLECULAR MICROBIOLOGY, 2000, 36 (01) : 183 - 192
  • [10] Felmingham D, 2001, CLIN MICROBIOL INFEC, V7, P2, DOI 10.1046/j.1469-0691.2001.0070s3002.x